News | July 14, 2008

Epocrates Drug, Formulary Application Available for iPhone, iPod

July 15, 2008 - Epocrates Inc. announced that its mobile drug and formulary reference, reportedly used by more than 500,000 healthcare professionals, can be downloaded free for the iPhone and iPod touch from the Apple App Store after Epocrates registration.

In addition, for the first time, the Epocrates Rx mobile application will feature pill pictures and a drug identification tool, providing more visual cues and resources for today's busy physicians. With enhanced functionality, clinicians can show their patients pictures of a newly prescribed drug, or identify a patient's existing medication with a physical description (e.g., round, blue and scored) when the name cannot be recalled.

"I believe Epocrates on the iPhone is an essential tool for the medical community - it is the one native application most healthcare professionals cannot live without," said Dr. Michael Salesin, Wayne State University School of Medicine. "Many of my colleagues have been waiting for the Epocrates application before purchasing the iPhone. I guarantee it's going to be the first download on many devices, and immediately put to use with patients."

Epocrates software is used by clinicians worldwide to reference a host of drug information, such as dosing, interactions and health plan coverage.

The Epocrates free application is available from Apple's App Store on iPhone and iPod touch or at www.itunes.com/appstore.

For more information: www.epocrates.com/company

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init